ZCCHC14

Across TCGA pan-cancer cohorts, ZCCHC14 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZCCHC14 data layer compared with 20 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ZCCHC14 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ZCCHC14 expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

GBM, LUAD, and PDAC are the cancer types where ZCCHC14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.667	0.395	<.001	20	view →
LUAD	DFS	Quartile	All	0.416	0.846	.005	7	view →
PDAC	OS	Tertile	All	1.000	0.870	.043	1	view →
LSCC	DFS	Median	All	0.917	0.998	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZCCHC14–GBM (OS)

Open the GBM breakdown →